CANF Annual SG&A
$2.96 M
-$188.00 K-5.98%
31 December 2023
Summary:
As of January 23, 2025, CANF annual selling, general & administrative expenses is $2.96 million, with the most recent change of -$188.00 thousand (-5.98%) on December 31, 2023. During the last 3 years, it has risen by +$4000.00 (+0.14%). CANF annual SG&A is now -34.61% below its all-time high of $4.52 million, reached on December 31, 2013.CANF Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CANF Quarterly SG&A
N/A
30 June 2024
Summary:
CANF quarterly selling, general & administrative expenses is not available.CANF Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CANF TTM SG&A
-$477.75 M
+$146.03 M+23.41%
30 June 2024
Summary:
As of January 23, 2025, CANF TTM selling, general & administrative expenses is -$477.75 million, with the most recent change of +$146.03 million (+23.41%) on June 30, 2024. Over the past year, it has dropped by -$480.79 million (-15825.74%). CANF TTM SG&A is now -691.95% below its all-time high of $4.57 million, reached on March 1, 2014.CANF TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CANF Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -6.0% | - | -10000.0% |
| 3 y3 years | +0.1% | - | -10000.0% |
| 5 y5 years | -6.5% | - | -10000.0% |
CANF Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -23.1% | at low | at high | +23.4% | ||
| 5 y | 5-year | -23.1% | +0.1% | -41.3% | +23.4% | ||
| alltime | all time | -34.6% | +74.6% | -692.0% | +23.4% |
Can-Fite BioPharma Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | $2.96 M(-6.0%) | $722.00 K(-5.2%) | $2.96 M(-3.4%) |
| Sept 2023 | - | $762.00 K(+22.1%) | $3.06 M(+0.7%) |
| June 2023 | - | $624.00 K(-26.3%) | $3.04 M(-6.1%) |
| Mar 2023 | - | $847.00 K(+2.5%) | $3.24 M(+3.0%) |
| Dec 2022 | $3.14 M(-18.3%) | $826.00 K(+11.5%) | $3.14 M(-8.8%) |
| Sept 2022 | - | $741.00 K(-9.9%) | $3.45 M(-2.3%) |
| June 2022 | - | $822.00 K(+9.0%) | $3.53 M(-1.5%) |
| Mar 2022 | - | $754.00 K(-33.3%) | $3.58 M(-6.8%) |
| Dec 2021 | $3.85 M(+30.3%) | $1.13 M(+37.6%) | $3.85 M(+9.2%) |
| Sept 2021 | - | $822.00 K(-6.2%) | $3.52 M(+3.9%) |
| June 2021 | - | $876.00 K(-13.8%) | $3.39 M(+3.8%) |
| Mar 2021 | - | $1.02 M(+25.9%) | $3.26 M(+10.6%) |
| Dec 2020 | $2.95 M(-3.7%) | $807.00 K(+17.1%) | $2.95 M(-1.2%) |
| Sept 2020 | - | $689.00 K(-8.4%) | $2.99 M(-6.2%) |
| June 2020 | - | $752.00 K(+7.0%) | $3.19 M(-0.4%) |
| Mar 2020 | - | $703.00 K(-16.6%) | $3.20 M(+4.4%) |
| Dec 2019 | $3.06 M(-3.0%) | - | - |
| Dec 2019 | - | $843.00 K(-5.0%) | $3.06 M(+2.3%) |
| Sept 2019 | - | $887.00 K(+15.8%) | $2.99 M(+12.0%) |
| June 2019 | - | $766.00 K(+35.1%) | $2.67 M(-5.2%) |
| Mar 2019 | - | $567.00 K(-26.6%) | $2.82 M(-10.8%) |
| Dec 2018 | $3.16 M(+14.6%) | - | - |
| Dec 2018 | - | $773.00 K(+36.3%) | $3.16 M(+3.8%) |
| Sept 2018 | - | $567.00 K(-37.8%) | $3.04 M(-5.0%) |
| June 2018 | - | $912.00 K(+0.6%) | $3.20 M(+10.4%) |
| Mar 2018 | - | $907.00 K(+38.1%) | $2.90 M(+5.3%) |
| Dec 2017 | $2.76 M(+4.6%) | - | - |
| Dec 2017 | - | $657.00 K(-9.6%) | $2.76 M(+4.5%) |
| Sept 2017 | - | $727.00 K(+19.0%) | $2.64 M(-2.8%) |
| June 2017 | - | $611.00 K(-19.8%) | $2.71 M(-2.1%) |
| Mar 2017 | - | $762.00 K | $2.77 M |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2016 | $2.64 M(-2.3%) | - | - |
| Dec 2016 | - | $538.70 K(-32.9%) | $2.64 M(-14.1%) |
| Sept 2016 | - | $802.60 K(+19.7%) | $3.07 M(+11.2%) |
| June 2016 | - | $670.40 K(+7.2%) | $2.76 M(+2.2%) |
| Mar 2016 | - | $625.30 K(-35.6%) | $2.70 M(-0.0%) |
| Dec 2015 | $2.70 M(-8.2%) | - | - |
| Dec 2015 | - | $970.90 K(+96.8%) | $2.70 M(+5.0%) |
| Sept 2015 | - | $493.30 K(-19.1%) | $2.57 M(-0.9%) |
| June 2015 | - | $609.80 K(-2.6%) | $2.60 M(-4.8%) |
| Mar 2015 | - | $625.80 K(-25.8%) | $2.73 M(-7.3%) |
| Dec 2014 | $2.94 M(-34.9%) | - | - |
| Dec 2014 | - | $843.10 K(+63.1%) | $2.94 M(-25.1%) |
| Sept 2014 | - | $516.80 K(-30.1%) | $3.92 M(-7.7%) |
| June 2014 | - | $739.60 K(-12.0%) | $4.25 M(-6.9%) |
| Mar 2014 | - | $840.70 K(-54.0%) | $4.57 M(+2.0%) |
| Dec 2013 | $4.52 M(+85.4%) | $1.83 M(+116.3%) | $4.48 M(+26.4%) |
| Sept 2013 | - | $844.70 K(-19.9%) | $3.54 M(+10.9%) |
| June 2013 | - | $1.06 M(+40.6%) | $3.19 M(+16.2%) |
| Mar 2013 | - | $750.50 K(-15.8%) | $2.75 M(+10.1%) |
| Dec 2012 | $2.44 M(+41.3%) | - | - |
| Dec 2012 | - | $891.60 K(+80.0%) | $2.50 M(+25.8%) |
| Sept 2012 | - | $495.30 K(-18.9%) | $1.98 M(+1.3%) |
| June 2012 | - | $611.00 K(+22.7%) | $1.96 M(+7.2%) |
| Mar 2012 | - | $498.00 K(+31.1%) | $1.83 M(+1.8%) |
| Dec 2011 | $1.72 M(+1.9%) | - | - |
| Dec 2011 | - | $379.80 K(-19.3%) | $1.80 M(-10.0%) |
| Sept 2011 | - | $470.50 K(-2.0%) | $2.00 M(+5.8%) |
| June 2011 | - | $480.10 K(+3.1%) | $1.89 M(+34.1%) |
| Mar 2011 | - | $465.70 K(-19.6%) | $1.41 M(+49.5%) |
| Dec 2010 | $1.69 M | - | - |
| Dec 2010 | - | $579.10 K(+60.2%) | $940.60 K(+160.2%) |
| Sept 2010 | - | $361.50 K | $361.50 K |
FAQ
- What is Can-Fite BioPharma annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Can-Fite BioPharma?
- What is Can-Fite BioPharma annual SG&A year-on-year change?
- What is the all time high quarterly SG&A for Can-Fite BioPharma?
- What is Can-Fite BioPharma TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Can-Fite BioPharma?
- What is Can-Fite BioPharma TTM SG&A year-on-year change?
What is Can-Fite BioPharma annual selling, general & administrative expenses?
The current annual SG&A of CANF is $2.96 M
What is the all time high annual SG&A for Can-Fite BioPharma?
Can-Fite BioPharma all-time high annual selling, general & administrative expenses is $4.52 M
What is Can-Fite BioPharma annual SG&A year-on-year change?
Over the past year, CANF annual selling, general & administrative expenses has changed by -$188.00 K (-5.98%)
What is the all time high quarterly SG&A for Can-Fite BioPharma?
Can-Fite BioPharma all-time high quarterly selling, general & administrative expenses is $1.83 M
What is Can-Fite BioPharma TTM selling, general & administrative expenses?
The current TTM SG&A of CANF is -$477.75 M
What is the all time high TTM SG&A for Can-Fite BioPharma?
Can-Fite BioPharma all-time high TTM selling, general & administrative expenses is $4.57 M
What is Can-Fite BioPharma TTM SG&A year-on-year change?
Over the past year, CANF TTM selling, general & administrative expenses has changed by -$480.79 M (-15825.74%)